Display options
Share it on

Oncoimmunology. 2016 Oct 14;5(12):e1242546. doi: 10.1080/2162402X.2016.1242546. eCollection 2016.

Lower incidence of acute GVHD is associated with the rapid recovery of CD4.

Oncoimmunology

Yu Wang, Xiang-Yu Zhao, Lan-Ping Xu, Xiao-Hui Zhang, Wei Han, Huan Chen, Feng-Rong Wang, Xiao-Dong Mo, Yuan-Yuan Zhang, Xiao-Su Zhao, Kong Y, Kai-Yan Liua, Xiao-Jun Huang, Xue-Zhong Yu, Ying-Jun Chang

Affiliations

  1. Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, P.R. China.
  2. Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, P.R. China; Peking-Tsinghua Center for Life Sciences, Beijing, P.R. China.
  3. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA; Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.

PMID: 28180031 PMCID: PMC5215191 DOI: 10.1080/2162402X.2016.1242546

Abstract

To investigate the effects of non-inherited maternal antigen (NIMA) on clinical outcomes and immune recovery, especially of regulatory T cells (Tregs), in patients who underwent unmanipulated haploidentical transplantation. A retrospective cohort (n = 57) and a prospective cohort (n = 88) were included. All patients received haploidentical allografts from sibling donors. Reconstitution of immune subsets, including Tregs, was determined using multicolor flow cytometry. In the retrospective cohort, the cumulative incidence of grades II-IV acute GVHD in patients with NIMA-mismatched donors was significantly lower than that of cases with NIPA-mismatched donors (14.8% vs. 43.30%,

Keywords: Graft-versus-host disease; haploidentical stem cell transplantation; immune reconstitution; non-inherited maternal antigen; regulatory T cells

References

  1. Biol Blood Marrow Transplant. 2009 Feb;15(2):257-65 - PubMed
  2. Blood. 2015 Jun 18;125(25):3956-62 - PubMed
  3. Bone Marrow Transplant. 2009 Sep;44(5):327-9 - PubMed
  4. J Hematol Oncol. 2016 Apr 12;9:35 - PubMed
  5. Blood. 2002 Mar 1;99(5):1572-7 - PubMed
  6. Blood. 2003 Apr 15;101(8):3334-6 - PubMed
  7. J Clin Immunol. 2008 May;28(3):276-83 - PubMed
  8. Blood. 2016 Feb 4;127(5):646-57 - PubMed
  9. Br J Haematol. 2004 Nov;127(4):474-5 - PubMed
  10. Haematologica. 2007 Mar;92(3):414-7 - PubMed
  11. J Hematol Oncol. 2015 Jul 10;8:84 - PubMed
  12. Bone Marrow Transplant. 2004 Aug;34(4):373-5 - PubMed
  13. Biol Blood Marrow Transplant. 2014 Apr;20(4):440-9 - PubMed
  14. Blood. 2004 Feb 1;103(3):1140-6 - PubMed
  15. Sci Transl Med. 2013 Nov 13;5(211):211ra157 - PubMed
  16. Blood. 2015 May 7;125(19):3024-31 - PubMed
  17. PLoS One. 2016 Jun 08;11(6):e0156777 - PubMed
  18. N Engl J Med. 2011 Dec 1;365(22):2055-66 - PubMed
  19. Leukemia. 2011 Jan;25(1):121-9 - PubMed
  20. J Clin Invest. 2015 Sep;125(9):3627-41 - PubMed
  21. Bone Marrow Transplant. 2004 Nov;34(10):897-9 - PubMed
  22. Leukemia. 2015 Feb;29(2):396-405 - PubMed
  23. J Exp Med. 2002 Aug 5;196(3):389-99 - PubMed
  24. Nat Rev Clin Oncol. 2016 Jan;13(1):10-24 - PubMed
  25. Blood. 2014 Oct 23;124(17):2735-43 - PubMed
  26. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 - PubMed
  27. Semin Hematol. 2016 Apr;53(2):82-9 - PubMed
  28. Blood. 2004 Dec 1;104(12):3821-8 - PubMed
  29. J Clin Immunol. 2012 Apr;32(2):268-80 - PubMed
  30. Bone Marrow Transplant. 2013 Jun;48(6):859-64 - PubMed
  31. Blood. 2009 Feb 19;113(8):1829-33 - PubMed
  32. Blood. 2014 Aug 7;124(6):843-50 - PubMed
  33. Blood. 2015 Aug 20;126(8):1033-40 - PubMed
  34. Biol Blood Marrow Transplant. 2008 Jun;14 (6):641-50 - PubMed
  35. Bone Marrow Transplant. 2014 Mar;49(3):426-33 - PubMed
  36. Blood. 2006 Jan 1;107(1):404-9 - PubMed
  37. Br J Haematol. 1997 Jun;97(4):855-64 - PubMed
  38. N Engl J Med. 1982 Feb 18;306(7):392-7 - PubMed

Publication Types